Efficacy and safety of first-line bevacizumab combined with paclitaxel in 220 patients with metastatic breast cancer: The Hungarian AVAREG observational study

被引：0
|
作者：
Dank, Magdolna
Budi, Laszlo
Landherr, Laszlo
Piko, Bela
Mangel, Laszlo
Erfan, Jozsef
Cseh, Jozsef
Ruzsa, Agnes
Nagy, Andras
机构：
[1] Semmelweis Univ, H-1085 Budapest, Hungary
[2] BAZ Cty Hosp, Miskolc, Hungary
[3] Uzsoki St Hosp, Budapest, Hungary
[4] Bekes Cty Pandy Kalman Hosp, Gyula, Hungary
[5] Univ Pecs, Fac Med, Pecs, Hungary
[6] Josa Andras Oktata Korhaz, Nyiregyhaza, Hungary
[7] Fejer Cty St George Hosp, Szekesfehervar, Hungary
[8] Zala Cty Hosp, Zalaegerszeg, Hungary
[9] Roche Hungary Ltd, Budaors, Hungary
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12022
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
    Montero, Alberto J.
    Avancha, Kiran
    Glueck, Stefan
    Lopes, Gilberto
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 747 - 751
  • [22] The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
    Montero, A. J.
    Gluck, S.
    Lopes, G. D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study
    Francois, Eric
    Mineur, Laurent
    Deplanque, Gael
    Laplaige, Philippe
    Smith, Denis
    Gourgou, Sophie
    Tanang, Alexandre
    Ionescu-Goga, Miruna
    Veerabudun, Kalaivani
    Lelarge, Yoann
    Kim, Stefano
    Rollot, Florence
    CLINICAL COLORECTAL CANCER, 2020, 19 (03) : E100 - E109
  • [24] Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer.
    Lo, S. S.
    Guo, R.
    Czaplicki, K. L.
    Robinson, P. A.
    Gaynor, E.
    Barhamand, F. B.
    Schulz, W. C.
    Kash, J. J.
    Horvath, L. E.
    Bayer, R. A.
    Petrowsky, C.
    De la Torre, R.
    Park, J. H.
    Albain, K. S.
    CANCER RESEARCH, 2012, 72
  • [25] A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer
    Brufsky, Adam
    Hoelzer, Karen
    Beck, Thaddeus
    Whorf, Robert
    Keaton, Mark
    Nadella, Padma
    Krill-Jackson, Elisa
    Kroener, Joan
    Middleman, Edward
    Frontiera, Michael
    Paul, Devchand
    Panella, Timothy
    Bromund, Jane
    Zhao, Luping
    Orlando, Mauro
    Tai, Fritz
    Marciniak, Martin D.
    Obasaju, Coleman
    Hainsworth, John
    CLINICAL BREAST CANCER, 2011, 11 (04) : 211 - 220
  • [26] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
  • [27] Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
    Dyar, Stephen
    Moreno-Aspitia, Alvaro
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2011, 5 : 239 - 246
  • [28] First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab
    Fujii, Teruhiko
    Takahashi, Hiroki
    Matsubayashi, Roka Namoto
    Inoue, Yuka
    Takenaka, Miki
    Toh, Uhi
    Kage, Masayoshi
    Yamana, Hideaki
    Shirouzu, Kazuo
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 583 - 593
  • [29] Use of bevacizumab as a first-line treatment for metastatic breast cancer
    Manso, L.
    Moreno, F.
    Marquez, R.
    Castelo, B.
    Arcediano, A.
    Arroyo, M.
    Ballesteros, A. I.
    Calvo, I.
    Echarri, M. J.
    Enrech, S.
    Gomez, A.
    Gonzalez del Val, R.
    Lopez-Miranda, E.
    Martin-Angulo, M.
    Martinez-Janez, N.
    Olier, C.
    Zamora, P.
    CURRENT ONCOLOGY, 2015, 22 (02) : E51 - E60
  • [30] Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Untch, M
    Lisboa, B
    Kohler, G
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 35 - 39
12345